Deals

Vir Biotechnology and Gilead Strike Collaboration to Engineer Three PRO‑XTEN Dual‑Masked T‑Cell Engagers – Deal Worth Up to USD 1.88 Billion in Milestones
Gilead SciencesMulti-specific antibodies

Vir Biotechnology and Gilead Strike Collaboration to Engineer Three PRO‑XTEN Dual‑Masked T‑Cell Engagers – Deal Worth Up to USD 1.88 Billion in Milestones

Vir Biotechnology, Inc. (NASDAQ: VIR) announced a collaboration and license agreement with Gilead Sciences to discover and engineer three novel PRO‑XTEN dual‑masked T‑cell engager (TCE) development candidates targeting selected solid…

Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties

Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties

Wuhan Hiteck Licenses HT006.2.2 rhNGF Eye Drops to Visara for Ex‑Greater China – Up to USD 111 Million Deal Advances Next‑Generation Neurotrophic Keratitis Therapy

Wuhan Hiteck Licenses HT006.2.2 rhNGF Eye Drops to Visara for Ex‑Greater China – Up to USD 111 Million Deal Advances Next‑Generation Neurotrophic Keratitis Therapy

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Sihuan Pharma Invests in Swiss Aesthetic Tech Company Suisselle, Secures Permanent Exclusive Distribution of CELLBOOSTER in China
HKG: 0460Medical aesthetics

Sihuan Pharma Invests in Swiss Aesthetic Tech Company Suisselle, Secures Permanent Exclusive Distribution of CELLBOOSTER in China

Sichuan Biokin’s SystImmune Receives $250 Million Triggered by Phase 2/3 Milestone in EGFR×HER3 ADC
ADC / XDCBiokin Pharmaceutical

Sichuan Biokin’s SystImmune Receives $250 Million Triggered by Phase 2/3 Milestone in EGFR×HER3 ADC

BMS Acquires Orbital for $1.5 B in RNA‑Based Immunotherapy Deal
Bristol-Myers SquibbCAR-T

BMS Acquires Orbital for $1.5 B in RNA‑Based Immunotherapy Deal

PegBio Signs Non‑Binding Term Sheet with UAE‑Based PDC for Exclusive Middle East & Africa License of Visepegenatide
DiabetesHKG: 2565

PegBio Signs Non‑Binding Term Sheet with UAE‑Based PDC for Exclusive Middle East & Africa License of Visepegenatide

Show More